Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
https://seekingalpha.com/article/4683008-nektar-therapeutics-sees-something-in-data-puts-its-drug-to-test?source=feed_all_articles
Apr 09, 2024 - Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata. See why NKTR stock is a Hold.
0
Wall Street Analysts See PagSeguro Digital (PAGS) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2252542/wall-street-analysts-see-pagseguro-digital-pags-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2252542
Apr 09, 2024 - Based on the average brokerage recommendation (ABR), PagSeguro Digital (PAGS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
0
China's commercial property segment is seeing some bright spots amid a slump in the wider realty sector
https://www.cnbc.com/2024/04/11/chinas-commercial-property-segment-is-seeing-some-bright-spots-.html
Apr 10, 2024 - China's commercial property sector is seeing pockets of demand amid an overall real estate slump.
0
Modelo maker Constellation Brands is primed for market share gains but we still see one issue with the company
https://www.cnbc.com/2024/04/07/modelo-maker-constellation-brands-is-primed-for-market-share-gains.html
Apr 07, 2024 - Constellation Brands is positioned for market share gains with a strong business outlook despite this one overhang.
0
Look Up and See the Future
https://www.fool.com/investing/2024/04/10/look-up-and-see-the-future/?source=iedfolrf0000001
Apr 10, 2024 - Sierra Space is trying to build an economy in low Earth orbit (LEO).
0
U.S. Stocks Continue To See Significant Weakness After Early Sell-Off
https://www.rttnews.com/story.aspx?Id=3438141
Apr 10, 2024 - After moving sharply lower early in the session, stocks continue to see significant weakness in afternoon trading on Wednesday. The major averages have all moved to the downside after closing mixed in each of the two previous sessions.
0
FDA chief sees no reason for delay in cannabis rescheduling
https://seekingalpha.com/news/4089059-fda-chief-sees-no-reason-for-delay-in-cannabis-rescheduling?source=feed_sector_healthcare
Apr 11, 2024 - The head of the FDA, Robert Califf, argues that there is no reason for the DEA to delay its decision on rescheduling marijuana. Read more here.
0
Core & Main (CNM) Sees a More Significant Dip Than Broader Market: Some Facts to Know
https://www.zacks.com/stock/news/2254837/core-main-cnm-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2254837
Apr 12, 2024 - Core & Main (CNM) concluded the recent trading session at $56.34, signifying a -1.47% move from its prior day's close.
0
Wall Street Analysts See High Tide (HITI) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2254428/wall-street-analysts-see-high-tide-hiti-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2254428
Apr 12, 2024 - According to the average brokerage recommendation (ABR), one should invest in High Tide (HITI). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
0
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
https://seekingalpha.com/news/4089446-needham-sees-bsx-cnmd-rmd-beating-street-despite-medtech-slow-down?source=feed_sector_healthcare
Apr 14, 2024 - Needham estimates Q1 medtech sales grew less than expected, but that Boston Scientific, CONMED, ResMed and Surmodics should still be able to beat the Street. Read more here.
0